source
- Solstice Oncology secures $225M Series A to launch FDA-cleared Phase 2 CTLA-4 antibody trialSolstice Oncology, a cancer-focused startup that emerged from stealth in February, announced a $225 million Series A financing round to fund its early-stage programs. The capital will be used to a…
- AMA chief says AI will augment, not replace, physiciansJohn Whyte, the chief executive of the American Medical Association, wrote an opinion piece asserting that artificial intelligence should work alongside doctors rather than take their place. He po…